Title of article
Dual Antiplatelet Therapy and Heparin “Bridging” Significantly Increase the Risk of Bleeding Complications After Pacemaker or Implantable Cardioverter-Defibrillator Device Implantation
Author/Authors
Tompkins، نويسنده , , Christine and Cheng، نويسنده , , Alan and Dalal، نويسنده , , Darshan and Brinker، نويسنده , , Jeffrey A. and Leng، نويسنده , , Charles T. and Marine، نويسنده , , Joseph E. and Nazarian، نويسنده , , Saman and Spragg، نويسنده , , David D. and Sinha، نويسنده , , Sunil and Halperin، نويسنده , , Henry and Tomaselli، نويسنده , , Gordon F. and Berger، نويسنده , , Ronald D. and Calkins، نويسنده , , Hugh and Henrikson، نويسنده , , Charles A.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2010
Pages
7
From page
2376
To page
2382
Abstract
Objectives
tudy was designed to assess the risk of significant bleeding complications in patients receiving antiplatelet or anticoagulation medications at the time of implantable cardioverter-defibrillator (ICD) device implantation.
ound
ocedural management of antiplatelet or anticoagulation therapy at the time of device implantation remains controversial.
s
formed a retrospective chart review of bleeding complications in all patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. Aspirin or clopidogrel use was defined as taken within 5 days of the procedure. A significant bleeding complication was defined as need for pocket exploration or blood transfusion; hematoma requiring pressure dressing or change in anticoagulation therapy; or prolonged hospitalization.
s
1,388 device implantations, 71 had bleeding complications (5.1%). Compared with controls not taking antiplatelet agents (n = 255), the combination of aspirin and clopidogrel (n = 139) significantly increased bleeding risk (7.2% vs. 1.6%; p = 0.004). In patients taking aspirin alone (n = 536), bleeding risk was marginally higher than it was for patients taking no antiplatelet agents (3.9% vs. 1.6%, p = 0.078). The use of periprocedural heparin (n = 154) markedly increased risk of bleeding when compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258; 14.3% vs. 4.3%; p < 0.001) and compared with patients receiving no anticoagulation therapy (14.3% vs.1.6%; p < 0.0001). There was no statistical difference in bleeding risk between patients continued on warfarin with an INR ≥1.5 (n = 46) and patients who had warfarin withheld until the INR was normal (n = 258; 6.5% vs. 4.3%; p = 0.50).
sions
ntiplatelet therapy and periprocedural heparin significantly increase the risk of bleeding complications at the time of pacemaker or ICD implantation.
Keywords
Antiplatelet , Pacemaker , Anticoagulation , Complications , defibrillator
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2010
Journal title
JACC (Journal of the American College of Cardiology)
Record number
1747584
Link To Document